A5067251812- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Multiple Myeloma Research and Treatments
- Cancer, Lipids, and Metabolism
- Urologic and reproductive health conditions
- Adrenal and Paraganglionic Tumors
- Hematological disorders and diagnostics
- Medical Imaging and Pathology Studies
- Lymphoma Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Peptidase Inhibition and Analysis
- Cancer, Hypoxia, and Metabolism
- Neuroendocrine Tumor Research Advances
- Pituitary Gland Disorders and Treatments
- MRI in cancer diagnosis
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Advanced X-ray and CT Imaging
- Head and Neck Cancer Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
National Institutes of Health
2016-2025
National Cancer Institute
2016-2025
Center for Cancer Research
2015-2024
University of Maryland Medical Center
2024
National Center for Advancing Translational Sciences
2024
University of Maryland, Baltimore
2024
National Cancer Institute
2024
Johns Hopkins University
2014-2019
Johns Hopkins Medicine
2015-2019
ORCID
2019
The identification of oncogenic mutations in diffuse large B-cell lymphoma (DLBCL) has led to the development drugs that target essential survival pathways, but whether targeting multiple pathways may be curative DLBCL is unknown.
There has been no established qualitative system of interpretation for therapy response assessment using PET/CT head and neck cancers. The objective this study was to validate the Hopkins assess survival outcome in squamous cell cancer patients (HNSCC).The included 214 biopsy-proven HNSCC who underwent a posttherapy study, between 5 24 wk after completion treatment. median follow-up 27 mo. studies were interpreted by 3 nuclear medicine physicians, independently. scored 5-point scale, primary...
Purpose To compare utility of T2-weighted (T2W) MRI and diffusion-weighted (DWI-MRI) obtained with without an endorectal coil at 3 Tesla (T) for localizing prostate cancer. Materials Methods This Institutional Review Board-approved study included 20 patients (median prostate-specific antigen, 8.4 ng/mL). Patients underwent consecutive MRIs 3T, first a surface alone, then combination surface, coils (dual coil) followed by robotic assisted radical prostatectomy. Lesions were mapped time...
To characterize uptake of 1-amino-3-fluorine 18-fluorocyclobutane-1-carboxylic acid ((18)F FACBC) in patients with localized prostate cancer, benign prostatic hyperplasia (BPH), and normal tissue to evaluate its potential utility delineation intraprostatic cancers histopathologically confirmed cancer comparison magnetic resonance (MR) imaging.Institutional review board approval written informed consent were obtained for this HIPAA-compliant prospective study. Twenty-one men underwent dynamic...
This work characterizes the uptake of <sup>11</sup>C-acetate in prostate cancer (PCa), benign hyperplasia, and normal tissue comparison with multiparametric MRI, whole-mount histopathology, clinical markers to evaluate potential utility for delineating intraprostatic tumors a population patients localized PCa. <b>Methods:</b> Thirty-nine men presumed PCa underwent dynamic–static abdominal–pelvic PET/CT 30 min 3-T MRI before prostatectomy. images were registered MR using pelvic bones initial...
Conventional imaging modalities (CIMs) have limited sensitivity and specificity for detection of metastatic prostate cancer. We examined the potential a first-in-class radiofluorinated small-molecule inhibitor prostate-specific membrane antigen (PSMA), <i>N</i>-[<i>N</i>-[(<i>S</i>)-1,3-dicarboxypropyl]carbamoyl]-4-<sup>18</sup>F-fluorobenzyl-l-cysteine (<sup>18</sup>F-DCFBC), to detect hormone-naïve (HNPC) castration-resistant cancer (CRPC). <b>Methods:</b> Seventeen patients were...
Automatic detection and characterization of cancer are important clinical needs to optimize early treatment. We developed a deep, semisupervised transfer learning approach for fully automated, whole-body tumor segmentation prognosis on PET/CT. <b>Methods:</b> This retrospective study consisted 611 <sup>18</sup>F-FDG PET/CT scans patients with lung cancer, melanoma, lymphoma, head neck breast 408 prostate-specific membrane antigen (PSMA) prostate cancer. The had nnU-net backbone learned the...
This prospective pilot study evaluated the ability of Na<sup>18</sup>F PET/CT to detect and monitor bone metastases over time its correlation with clinical outcomes survival in advanced prostate cancer. <b>Methods:</b> Sixty cancer patients, including 30 without known by conventional imaging, underwent at baseline, 6 mo, 12 mo. Positive lesions were verified on follow-up scans. Changes SUVs lesion number correlated prostate-specific antigen change, impression, overall survival....
Mantle cell lymphoma (MCL) is biologically and clinically heterogeneous would benefit from prognostic biomarkers to guide management. Circulating tumor DNA (ctDNA) a novel biomarker in diffuse large B-cell that may have applicability MCL. We analyzed ctDNA dynamics previously untreated patients with MCL who received induction therapy bortezomib DA-EPOCH-R for 6 cycles followed by random assignment observation or maintenance responding prospective phase 2 study. Most also underwent initial...
We evaluated the kinetics of <sup>18</sup>F-sodium fluoride (NaF) and reassessed recommended dose, optimal uptake period, reproducibility using a current-generation PET/CT scanner. <b>Methods:</b> In this prospective study, 73 patients (31 with multiple myeloma or precursor disease 42 prostate cancer) were injected mean administered dose 141 MBq <sup>18</sup>F-NaF. Sixty underwent 3 sequential sessions 3-dimensional torso beginning approximately 15 min after <sup>18</sup>F-NaF injection,...
515 Background: Tolerability and efficacy of CaboNivo CaboNivoIpi were demonstrated in the initial phase I cohort, prompting longer follow-up addition expansion cohorts to further evaluate both combinations Methods: Phase cohort had 7 dose levels (DL). Recommended 2 doses for CaboNivo=Cabo 40mg/Nivo 3mg/kg (DL2) & CaboNivoIpi=Cabo 3mg/kg/Ipi 1mg/kg (DL6) (Nadal ESMO 2017).In cohorts, pts treated: [1] DL8: Cabo 1mg/kg/Ipi 3mg/kg; [2]DL2: mUC, metastatic renal cell carcinoma (mRCC),...
Our objective was to investigate the lesion detection rate of <sup>18</sup>F-DCFPyL PET/CT, a prostate-specific membrane antigen (PSMA)–targeted PET agent, in patients with biochemically relapsed prostate cancer after primary local therapy. <b>Methods:</b> This prospective institutional review board–approved study 90 documented biochemical recurrence (median [PSA], 2.5 ng/mL; range, 0.21–35.5 ng/mL) and negative results on conventional imaging therapies, including radical prostatectomy...
The overexpression and overactivation of hepatocyte growth factor receptor (Met) in various cancers has been linked to increased proliferation, progression metastatic disease, drug resistance. Developing a PET agent assess Met expression would aid the diagnosis monitoring responses Met-targeted therapies. In these studies, onartuzumab, experimental therapeutic 1-armed monoclonal antibody, was radiolabeled with <sup>76</sup>Br or <sup>89</sup>Zr evaluated as an imaging Met-expressing cell...